🇺🇸 IONIS PHARMACEUTICALS INCIONS

Company Update Form 8-K 23-10-2026 13:41:58 EDT

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Partner Roche announced Phase 3 IMAgINATION study data showing sefaxersen achieved a 43.1% reduction in proteinuria relative to placebo at 37 weeks.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest